Perinatal mortality · women with gestational diabetes mellitus
1 finding from 1 review
Large‐for‐gestational age · women with gestational diabetes mellitus
It is very uncertain whether continuous glucose monitoring system changes large‐for‐gestational age compared with self‐monitoring of glucose (very low certainty).
1 finding from 1 review
Death or serious morbidity composite · women with gestational diabetes mellitus
1 finding from 1 review
Neurosensory disability · women with gestational diabetes mellitus
1 finding from 1 review
Induction of labour · women with gestational diabetes mellitus
It is very uncertain whether telemedicine changes induction of labour compared with standard care (very low certainty).
1 finding from 1 review
Hypoglycaemia · women with gestational diabetes mellitus
It is very uncertain whether continuous glucose monitoring system changes hypoglycaemia compared with self‐monitoring of glucose (very low certainty).
1 finding from 1 review
Adiposity · women with gestational diabetes mellitus
1 finding from 1 review
Type 2 diabetes mellitus · women with gestational diabetes mellitus
1 finding from 1 review
Perineal trauma · women with gestational diabetes mellitus
1 finding from 1 review
Postnatal depression · women with gestational diabetes mellitus
1 finding from 1 review
Postnatal weight retention or return to pre‐pregnancy weight · women with gestational diabetes mellitus
1 finding from 1 review
Perinatal mortality · women with gestational diabetes mellitus
1 finding from 1 review
Large‐for‐gestational age · women with gestational diabetes mellitus
It is very uncertain whether telemedicine changes large‐for‐gestational age compared with standard care (very low certainty).
1 finding from 1 review
Time to progression · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in time to progression compared with other endocrine treatment (moderate certainty).
1 finding from 1 review
Clinical benefit rate · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in clinical benefit rate compared with other endocrine treatment (high certainty).
1 finding from 1 review
All‐cause mortality · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in mortality compared with other endocrine treatment (high certainty).
1 finding from 1 review
Vasomotor toxicity · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in vasomotor toxicity compared with other endocrine treatment (high certainty).
1 finding from 1 review
Arthralgia · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in arthralgia compared with other endocrine treatment (high certainty).
1 finding from 1 review
Gynaecological toxicity · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in gynaecological toxicity compared with other endocrine treatment (high certainty).
1 finding from 1 review
Quality of life · women with hormone‐sensitive advanced breast cancer
1 finding from 1 review